Anika Therapeutics (ANIK) Share-based Compensation Growth (3y) (2014 - 2026)
Anika Therapeutics (ANIK) Share-based Compensation Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 10.06% |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 9.14% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 0.43% |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -8.13% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | -1.73% |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | -8.04% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Anika Therapeutics | 282.86 Mn | 244.45 Mn | 21.24 Mn | 293.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 293.86% |
| Mar 31, 2026 | 678.28% |
| Dec 31, 2025 | -1.69% |
| Sep 30, 2025 | -18.70% |
| Jun 30, 2025 | -14.53% |
| Mar 31, 2025 | 484.48% |
| Dec 31, 2024 | -10.69% |
| Sep 30, 2024 | 5.84% |
| Jun 30, 2024 | 69.52% |
| Mar 31, 2024 | 184.39% |
| Dec 31, 2023 | 38.63% |
| Sep 30, 2023 | 22.86% |
| Jun 30, 2023 | -23.87% |
| Mar 31, 2023 | 26.70% |
| Dec 31, 2022 | -46.71% |
| Sep 30, 2022 | -43.03% |
| Jun 30, 2022 | 68.57% |
| Mar 31, 2022 | 44.22% |
| Dec 31, 2021 | 47.73% |
| Sep 30, 2021 | 34.49% |